Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

is C patients with moderate to severe fibrosis or cirrhosis who failed prior treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy were retreated with PEGINTRON combination therapy. PEGINTRON combination therapy is the first and only pegylated interferon combination therapy approved in the European Union (EU) for retreating both hepatitis C relapsers and nonresponders.

Researchers also will present the final results of the COPILOT study, which evaluated the investigational use of low-dose PEGINTRON as maintenance therapy in chronic hepatitis C nonresponder patients with fibrosis or cirrhosis. The goal of maintenance therapy in this very hard-to-treat patient population is to prevent or delay the progression of liver disease, liver cancer or death.

Schering-Plough also is exploring novel therapeutic approaches to treating hepatitis C with boceprevir, its investigational oral HCV protease inhibitor currently in Phase II clinical development. Oral presentations of boceprevir data will include interim results from the HCV SPRINT-1 study in treatment-naive hepatitis C patients and final results of the HCV RESPOND-1 study in patients who were "null" responders to previous peginterferon and ribavirin combination therapy.

Key Data Presentations at EASL

PEGINTRON Oral Presentations

Final results of the IDEAL (Individualized Dosing Efficacy versus flat dosing to Assess optimaL pegylated interferon therapy) Phase IIIb study. Sulkowski, M. et al. Late-Breaker Parallel Session 16, Saturday, April 26, 4:45 p.m. Hall A.

Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): final results from the EPIC3 program. Poynard, T. et al. Late-Breaker Parallel Session 16, Saturday, April 26, 4:00 p.m. Hall A.

Colchicine versus peginterferon alfa 2b long term therapy: results of the 4 year COPILOT trial.
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  GenSpera, Inc. ... for the treatment of cancer, announces that Kareg ... , has issued the following research report on  ... Traube , Director of Research, Kareg Corporation, Initiating ... Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf ...
(Date:7/14/2014)... Calif. , July 14, 2014 /PRNewswire/ ... announces a technology partnership with global bioengineering ... its technology for quick-to-market products. ... and DNA2.0,s machine learning optimization technologies, such ... up the process of engineering proteins in ...
(Date:7/14/2014)... Ltd. (NASDAQ: SVA ), a leading provider of biopharmaceutical products ... its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at ... Shangdi Xi Road, Haidian District, Beijing , PRC. All ... vote and are invited to attend. The primary agenda of ... Yuk Lam Lo , Simon Anderson , Kenneth Lee ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3
(Date:7/14/2014)... July 14, 2014 BCC Research ... SYNTHETIC BIOLOGY: GLOBAL MARKETS , the global ... nearly $11.9 billion in 2018, with a five-year ... products account for the fastest growing segment, with ... Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, energy, ...
(Date:7/14/2014)... The Encino cosmetic dentist at Encino ... and porcelain veneers. These restorations are an excellent alternative ... greater loss of healthy tooth tissue. They work similarly ... on the tooth. Encino dentist Dr. Mastour and his ... they offer the most appropriate treatment recommendations for each ...
(Date:7/14/2014)... Gray HealthDay Reporter ... suggests that a faltering sense of smell might signal ... inexpensive, low-tech smell test could spot who needs more ... the decreased ability to identify odors was associated with ... Alzheimer,s disease. "We,re trying to be able to ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July ... linked to multiple health issues, but dementia isn,t one of ... widowhood may even delay dementia, the researchers found. "For ... was associated with a later age of developing full-blown dementia ... Bryan Woodruff. Woodruff, an assistant professor of neurology ...
(Date:7/14/2014)... Skin M.D. by ... on Monday, July 14th, located at 45 East ... last all week through Saturday, July 19th, with ... welcomed to attend. The business is owned by ... anti-aging, weight loss services, and sells high-end industry ...
Breaking Medicine News(10 mins):Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3
... hunger strike to protest against the raising of the Narmada ... attending on her Sunday. // ,"Medha Patkar has ... doctor at the All India Institute of Medical Sciences (AIIMS) ... ,AIIMS medical superintendent D.K. Sharma said that Patkar's ...
... strapped for cash are planning on letting go of staff and ... Hospital in Wolverhampton, a hospital in such a crisis which has ... hoping to save about ?2.5 million a year. The management hope ... medical secretary bill by sending voice recordings over the internet to ...
... a Melbourne study australians go to hospitals with injuiries due ... latest issue of the Medical// Journal of Australia. ... to falls of all hospital cases. ,Associate Professor ... Centre led the study and incorporated a falls prevention ...
... diet can influence corrective behaviour in prisoners.// ... product of poor nutrition was tested in a prison ... less violent when put on a diet rich in ... paper titled “Seafood Consumption and Homicide Mortality”, raised this ...
... UK has fallen to its lowest levels since such records ... Suicide Prevention Strategy. The report also shows //a drop in ... well as a decline in the number of suicides among ... major cause of preventable death in England and elsewhere. At ...
... chemicals that could trigger inflammation leading to deterioration of ... the crucial link between obesity and heart disease. ... that fat cells lying close to blood vessels in ... influence biological processes within the body, reported the online ...
Cached Medicine News:
... A surgically implanted bone growth stimulator ... EBI OsteoGen surgically implanted bone growth stimulator ... of nonunions when surgery is already planned ... concern. Because the OsteoGen is totally surgically ...
... contact between grant material and fracture ends ... bones., ,Grid-Like Format of Mesh Cathode Provides ... , ,The innovative Mesh Cathode of the ... and a scaffolding effect designed to increase ...
... Cystoscope System using EndoSheath Technology introduces ... urologists in both their hospitals and ... flexible cystoscope with the sterile, protective ... procedures, while minimizing the costs of ...
... Plasma-CISE™ (wire electrodes) and Plasma-CUT™ ... devices that produce precise, consistent ... spread and Vapor sealing of ... The devices provide excellent results ...
Medicine Products: